Moderna's $3.4 Billion Question: TD Cowen Sees the Peak, the Market Waits for the Proof

TD Cowen has more than doubled its price target on Moderna, lifting it from $40 to $90, yet the firm stopped well short of telling investors to buy. Its rating stays at "Hold." That combination — a target that more than doubles alongside an unchanged neutral stance — captures the tension running through the entire Moderna story right now: the long-range economics of its cancer vaccine have been reimagined, but the evidence to underwrite them is still sitting in a conference folder.

The number doing the heavy lifting is not the target itself. It is the peak-profit forecast behind it. TD Cowen now projects roughly $3.4 billion in peak revenue for intismeran by 2035, up from a prior estimate of $830 million. The revision rests on two opportunities: adjuvant melanoma and non-small cell lung cancer.

A forecast is not a cash flow

That $3.4 billion figure describes a possibility more than a decade out, and treating it as banked earnings would skip the most important part of the valuation exercise. A price target compresses a pile of assumptions into a single digit; the underlying projection at least shows where the optimism comes from. Medical promise still has to translate into durable commercial results, and the gap between the two is where Moderna's investment case will be won or lost.

The near-term scorecard arrives quickly. Full Phase 3 data from the INTerpath-001 trial are due at the ESMO congress on October 24, with an investor webcast scheduled the same day. The study tests intismeran autogene in combination with Keytruda against Keytruda alone in patients with resected high-risk melanoma. Moderna has also confirmed it will report third-quarter 2026 results on November 6, a date announced on October 13.

Those two events answer entirely different questions, and investors would do well not to blur them. The melanoma readout speaks to clinical substance. The quarterly report speaks to financial staying power. Neither one, on its own, validates a peak-profit estimate for 2035.

What the August headline left open

Moderna and Merck disclosed in August that INTerpath-001 met its goals across 1,137 patients with resected melanoma. Beyond the primary endpoint, the companies reported an improvement in distant metastasis-free survival versus Keytruda alone. Hitting those marks, however, does not settle everything about the regimen. The full dataset needs to show how decisively the combination prevents recurrence and how consistent that benefit looks across patient subgroups; tolerability data will help put the magnitude in perspective.

An overall survival benefit remains unknown, according to Swissinfo. Investors should not read the earlier topline as a demonstrated survival gain. What matters first is whether the extra protection against recurrence and spread is clinically convincing — because that is precisely what the higher revenue expectations will be measured against.

The bull case, and what could blunt it

If the details hold up, the path forward becomes clearer. A meaningful added benefit with acceptable tolerability could shore up planned regulatory discussions and reinforce the strategic weight of personalized cancer therapy within Moderna. Even a strong melanoma result would leave the transferability to other tumor types an open question, though — proof of concept in one setting is not confirmation across a pipeline.

The serious bear argument is not that the trial missed. It is that the benefit may prove less commercially robust than hoped. A modest advantage or unfavorable tolerability could temper expectations even after positive primary endpoints. Layered on top is the patient-specific manufacturing process, which could make any launch more complex, slower and costlier. Clinical success and swift commercialization deserve separate scorecards; strong data would not by itself clear that operational hurdle.

Finances add another constraint. Moderna's cash and equivalents are projected to fall from $6.9 billion at the end of June to $4.7–5.2 billion by year-end. That makes funding the rest of the development program a live consideration. Should approval or commercialization slip, investors may train more attention on the ongoing cash burn — and a loftier 2035 profit estimate would be no substitute for near-term balance-sheet resilience.

Two dates, two different tests

Saturday's ESMO presentation in Madrid, followed by an investor event on Sunday, is the next hard catalyst. A convincing added benefit with manageable side effects keeps the optimistic scenario for Moderna's cancer program intact. A weaker-than-hoped benefit would likely strip weight from the long-range profit number and push manufacturing complexity and cash needs to the foreground.

For shareholders, the useful discipline is to link the clinical result to the commercial one without conflating them. A statistically successful trial is the foundation. Whether it becomes a viable business depends on treatment benefit, tolerability and manufacturability. The coming details should sharpen that judgment — they will not deliver an approval or a commercial success in advance. The raised intismeran estimate is a weighty vote of confidence in the program's potential; the larger number now demands stronger proof.